Ascendis Pharma
$227.87Change from previous close: +0.25%Absolute change: +$0.56
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 1,303 | 1,179 | 826 | 1,090 | — |
| Current assets | 1,109 | 1,061 | 703 | 923 | — |
| Cash and equivalents | 616 | 560 | 392 | 445 | — |
| Short-term investments | — | 0.0 | 7.3 | 291 | 236 |
| Receivables | 158 | 177 | 55.8 | 25.6 | — |
| Inventory | 302 | 296 | 209 | 131 | — |
| Net property, plant and equipment | 146 | 98.7 | 111 | 129 | — |
| Goodwill | 3.5 | 3.5 | 3.5 | 3.5 | — |
| Other intangible assets | 0.2 | 0.5 | 0.9 | 1.3 | — |
| Long-term investments | 32.5 | 13.6 | 5.7 | 30.4 | — |
| Current liabilities | 1,069 | 908 | 737 | 717 | — |
| Accounts payable | 90.7 | 96.4 | 94.6 | 101 | — |
| Long-term debt | 385 | 365 | 223 | 95.4 | — |
| Total debt | 872 | 857 | 644 | 508 | — |
| Total liabilities | 1,465 | 1,285 | 971 | 826 | — |
| Total equity (incl. minority) | -163 | -106 | -146 | 263 | — |